Recent reports of increased serum levels of soluble fms-like tyrosine kinase 1 (sFlt-1) and decreased levels of placental growth factor (PlGF) suggest the key role of angiogenic factors in development of pre-eclampsia. PlGF is excreted in urine, and reduced urinary level has been suggested as a marker of this condition as well as help in its prediction. We measured urinary PlGF and creatinine values in 69 pregnant women (35 with pre-eclampsia and 34 normotensive controls). Over 70% patients had severe pre-eclampsia. Compared to controls, the urinary PlGF and PlGF/creatinine levels were significantly reduced in women with pre-eclampsia. The hospital stay was longer and fetal outcomes poorer in this group. Three normotensive women who showed very low levels developed pre-eclampsia 2-6 weeks later. Reduced urinary PlGF level in a pregnant woman is a marker of pre-eclampsia. The value of reduced urinary PlGF levels in predicting pre-eclampsia in currently normotensive pregnant women needs to be evaluated. A simple predictive test is likely to be of value in the developing countries.
Pre-eclampsia, a pregnancy-specific syndrome characterized by hypertension, proteinuria, and edema, is the leading cause of maternal and perinatal morbidity and mortality. 1, 2 Preeclampsia occurs only in the presence of placenta and its resolution begins with the removal of placenta.
Recent investigations indicate that imbalance of angiogenic factors may be responsible for at least two of preeclampsia's penotypes, hypertension, and proteinuria. [3] [4] [5] [6] [7] [8] [9] [10] Levels of circulatory soluble fms-like tyrosine kinase 1 (sFlt-1, also referred to as sVEGFR1) are increased, which may then bind the proangiogenic vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), thereby preventing their interaction with endothelial cell-surface receptors. 11 Infusion of adenoviruses transfected with sFlt-1 messenger ribonucleic acid in rats was followed by increased circulating sFlt-1 levels and appearance of hypertension, glomerular endotheliosis and proteinuria, the hallmarks of pre-eclampsia. 5, 12 Elevated sFlt-1 and decreased free PlGF and VEGF antedated the clinical signs. 3, 5, 13 However, routine measurement of these angiogenic mediators for ascertaining the risk of pre-eclampsia could be difficult, and an alternative, less invasive method more suited to routine clinical use is required.
In contrast to the large (110 kDa) sFlt-1, PlGF (30 kDa) and VEGF (45 kDa) cross the glomerular filtration barrier and appear in urine. Podocytes and tubular cells produce VEGF, 14, 15 and hence urinary VEGF cannot reflect circulating VEGF levels. In contrast, urinary PlGF is derived entirely from circulating blood and hence is likely to reflect the circulating angiogenic state. We examined the utility of reduced urinary PlGF as a marker of pre-eclampsia. Table 1 shows the clinical characteristics of controls and those with pre-eclampsia. There were no significant differences between groups in the maternal age and gestational age at the time of sampling. In all, 25 (71%) patients had severe pre-eclampsia at presentation. The pre-eclampsia group showed significantly lower urinary PlGF levels (18711.3 vs 205.87132.2 pg/ml, Po0.0001) and PlGF/creatinine ratio (26.1716 vs 258.57130.5 pg/mg, Po0.0001). Figure 1 shows the PlGF and PlGF/creatinine ratios according to the gestational age. The mean PlGF levels were 15 and 10 times lower before and after 32 weeks of gestation in the preeclampsia group. PlGF normalized for urinary creatinine was 10-and 11-fold lower in p32and 432-week gestational age groups, respectively. PlGF values were lower in normotensive pregnancies after 32 weeks of gestation (P ¼ 0.048). In the three normotensive women who developed pre-eclampsia later, the urine PlGF (18.3, 16.4 and 21.2 pg/ml) and PlGF/ creatinine (14.6, 25.5 and 17.1 pg/mg) levels were similar to those noted in those with pre-eclampsia. Post-hoc power analysis showed that the study had 490% power to detect difference between the different subgroups at 1% significance level.
RESULTS
Among the pre-eclamptic women, reduced urinary PlGF showed a significant correlation with elevated serum uric acid (P ¼ 0.031) and IUGR (P ¼ 0.046), but there was no correlation with systolic and diastolic blood pressures or severity of proteinuria.
Of the 31 normotensive women, three delivered before 37 weeks of gestation. Two had small-for-gestational-age babies. Out of the 35 cases with pre-eclampsia, 23 required delivery within 24 h of presentation. Live infants of appropriate weight for gestational age were delivered in 19 cases, 10 had small-for-gestational-age infants and six ended in stillbirths. Four infants required transfer to the neonatal intensive care unit. Women with pre-eclampsia had a significantly longer hospital stay (3.271.1 vs 0.970.3 days, Po0.01).
DISCUSSION
This prospective study confirms the hypothesis that urinary concentrations of PlGF are significantly lower in pregnant women with pre-eclampsia compared to normotensive controls. The difference is maintained after normalization for urinary creatinine concentrations. PlGF levels are lower in normotensive pregnant women after 32 weeks of gestation; hence, values in disease states should be compared with normal values at the appropriate gestation age. We found that urinary PlGF could differentiate women with pre-eclampsia from normotensive controls in our population (women from India), and confirmed the findings of Levine et al. 10 Reduced urinary PlGF level antedated the diagnosis of pre-eclampsia by several weeks in their cohort, a phenomenon noted in three cases in the present study too. These findings suggest that this test may be useful for predicting this disorder. This hypothesis needs to be tested prospectively in larger number of cases. A limitation of this study was the lack of patient groups with nonpre-eclamptic hypertension and intrauterine growth retardation without pre-eclampsia. A recent study has shown elevated urinary sFlt-1 levels in severe pre-eclampsia. 16 However, the significance of this finding is questionable as it was noted in patients who had disrupted glomerular filtration barrier and heavy proteinuria. VEGF and PlGF (angiogenic growth factors) are known to promote vascular endothelial proliferation and differentiation, cell migration, increase the vascular permeability, inhibit apoptosis, and mediate endothelium-dependent vasodilatation. 17 Clark et al. 18 first demonstrated that placenta secreted sFlt-1, and postulated its role in regulation of circulating VEGF during pregnancy. Maynard et al. 5 confirmed the relationship between excess placental production of sFlt-1 and endothelial dysfunction, hypertension, and proteinuria of pre-eclampsia. Increased sFlt-1 possibly limits the availability of VEGF and PlGF to cell-surface receptors, 5, 9 and these angiogenic proteins may serve as specific targets for therapeutic intervention to restore the angiogenic balance. It is therefore crucial to identify patients before clinical manifestations appear, and determination of urinary PlGF may serve this important role.
About 99% of all pregnancy-related deaths reported worldwide occur in developing nations. Pre-eclampsia, along with hemorrhage and infection, accounts for over 60% of these deaths. 19 There was no maternal death in the current study despite having a high proportion of patients with severe pre-eclampsia, possibly because they managed to reach a tertiary care hospital. However, their hospital stay was longer than controls. The poor fetal outcome in this group reflects the lack of timely recognition of the disease, culminating in development of complications before medical attention could be sought. The Prevention of Maternal Mortality Network has accepted the three-delay model, viz. delay in decision to seek care, delay in arrival at the point of care and delay in provision of adequate care, as the causes of high mortality. 20 The first two delays can be considerably mitigated by a reliable, valid, and economical test that could predict pre-eclampsia and prompt early referral. Being noninvasive, urine test would be superior to one that requires a blood draw. For it to be useful in remote areas of developing countries, the technology needs to be simplified to a point where the test does not require expensive equipments and can be performed by personnel with limited training.
MATERIALS AND METHODS
This prospective study was conducted at the Postgraduate Institute of Medical Education and Research, a large tertiary care referral hospital in north India. A total of 69 pregnant women (35 consecutive primigravid subjects with gestational ages ranging from 27 to 37 weeks referred with a diagnosis of pre-eclampsia and 34 normotensive controls) were enrolled. Pre-eclampsia was defined as new-onset elevated blood pressure (X140/90 mmHg) and proteinuria X2 þ by dipstick on two occasions at least 4 h apart. Anyone with one of the following (blood pressure X160/110 mmHg on two occasions 6 h apart, proteinuria X3 þ on spot sample or 5 g/24 h, intrauterine growth retardation, transaminitis, platelets o10 5 /mm 3 , headache, visual disturbances, symptoms of liver capsule distension, oliguria, or hemolysis, elevated liver enzymes and low platelets syndrome was classified as having severe pre-eclampsia. No subject had eclampsia. Control subjects (pregnant women without hypertension, proteinuria, or renal disease) were selected from the Obstetrics outpatient population of the Institute after 1:1 matching for age (within 1 year) and period of gestation (within 1 week). No subject had a comorbid condition such as diabetes, asthma, heart disease, kidney disease, autoimmune disease, urinary infection, or was a smoker. Published data 10 were used to determine the sample size. A minimum of six subjects were required in each subgroup for a double-sided power of 0.9 at an alpha of 0.01. All subjects who were approached consented to supply the urine sample, and there were no refusals.
Blood pressure, urine protein and uric acid values were recorded. Subjects were followed up until delivery. Babies with birth weight below the 10th percentile of gestational age were classified as smallfor-age. Three patients, normotensive at the time of sample collection, developed pre-eclampsia 3-6 weeks later and hence were excluded from analysis.
Spot urine samples (10 ml) were collected in sterile containers, centrifuged at 3000 g for 20 min at 41C and stored at À801C for subsequent determination of the PlGF level. PlGF was measured using a specific enzyme-linked immunosorbent assay kit according to the manufacturer's protocol (R&D Systems, Inc., Minneapolis, MN, USA). The inter-and intra-assay coefficients of variation were 9.6 and 4.2%, respectively. Urinary creatinine was measured using a commercial picric acid colorimetric assay (CRTN, Bayer Diagnostics India Ltd, Baroda, India).
PlGF levels are expressed as raw values and after normalization for urinary creatinine. Data are presented as mean7s.d. Subjects were divided according to the period of gestation into two groups (p32 and 432 weeks). Statistical analysis was carried out using Statistical package for Social Sciences vs 12.0. Normality of distribution was confirmed using a Q-Q plot. Groups were compared using the unpaired Student's 't'-test. Pearson's correlation was used to investigate the relationship between urinary PlGF and other clinical variables. A P-value of o0.05 was considered significant.
In conclusion, our results indicate that decreased urinary PlGF level is associated with pre-eclampsia, and may antedate its clinical manifestations. Its value in predicting the development of preeclampsia needs to be tested in prospective studies. Urinary PlGF holds promise as a noninvasive marker, but simpler methods for detection of low urinary PlGF are required to make it useful in areas with limited access to healthcare technology.
